Pharmacological therapy

Last updated

Pharmacological therapy, also known as pharmacotherapy or drug therapy, is defined as medical treatment that utilizes one or more pharmaceutical drugs to improve on-going symptoms (symptomatic relief), treat the underlying condition, or act as a prevention for other diseases (prophylaxis). Today's pharmacological therapy has evolved from a long history of medication use, and it has changed most rapidly in the last century due to advancements in drug discovery. The therapy is administered and adjusted by healthcare professionals according to the evidence-based guidelines and the patient's health condition. Personalized medicine also plays a crucial role in pharmacological therapy. Personalized medicine, or precision medicine, takes account of the patient's genetic variation, liver function, kidney function, etc, to provide a tailor-made treatment for a patient. In pharmacological therapy, pharmacists will also consider medication compliance. Medication compliance, or medication adherence, is defined as the degree to which the patient follows the therapy that is recommended by the healthcare professionals. [1]

Contents

History

Image of latex sap from a poppy plant. Opium is extracted from latex sap. Opium pod cut to demonstrate fluid extraction1.jpg
Image of latex sap from a poppy plant. Opium is extracted from latex sap.

From natural compounds to pharmaceutical drugs

The use of medicinal substances can be traced back to 4000 BC in the Sumer civilization. [2] Healers at the time (called apothecaries), for example, understood the application of opium for pain relief. [3] The history of natural remedies can also be found in other cultures, including traditional Chinese medicine in China and Ayurvedic medicine in India, which are still in use nowadays. [4] Dioscorides, a 1st -century Greek surgeon, described more than six hundred animals, plants, and their derivatives in his medical botany, which remained the most influential pharmacopeia for fourteen hundred years. [5] Besides substances derived from living organisms, metals, including copper, mercury, and antimony, were also used as medical therapies. [5] They were said to cure various diseases during the late Renaissance. In 1657, tartar emetic, which is an antimony compound, was credited with curing Louis XIV of typhoid fever. [5] The drug was also administered intravenously for the treatment of schistosomiasis in the 20th century. [6] However, due to the concern over acute and chronic antimony poisoning, the role of tartar emetic as an antischistosomal agent was gradually replaced after the advent of praziquantel. [6]

Other than using natural products, humans also learned to compound medicine by themselves. The first pharmaceutical text was found on clay tablets from the Mesopotamians, who lived around 2100 BC. [4] Later in the 2nd century AD, compounding was formally introduced by Galen as “a process of mixing two or more medicines to meet the individual needs of a patient”. [4] Initially, compounding was only done by individual pharmacists, but in the post-World War II period, pharmaceutical manufacturers surged in number and took over the role of making medicine. [2] Meanwhile, there was a marked increase in pharmaceutical research, which led to a growing number of new drugs. [2] Most drug discovery milestones were made in the last hundred years, from antibiotics to biologics, [4] contributing to the foundation of current pharmacological therapy.

Drug discovery

Penicillin chemical structure Penicillin core.svg
Penicillin chemical structure

Most drugs were discovered by empirical means, including observation, accident, and trial and error. [5] One famous example is the discovery of penicillin, the first antibiotic in the world. The substance was discovered by Alexander Fleming in 1928 after a combination of unanticipated events occurred in his laboratory during his summer vacation. [7] The Penicillium mold on the petri dish was believed to secrete a substance (later named "penicillin") that inhibited bacterial growth. [7] Large pharmaceutical companies then started to establish their microbiological departments and search for new antibiotics. [8] The screening program for antimicrobial compounds also led to the discovery of drugs with other pharmacological properties, such as immunosuppressants like Cyclosporin A. [8]

The drug-receptor recognition involves a "key", which is a ligand such as a drug, and a "lock", which is a receptor. Ligand-receptor interaction.png
The drug-receptor recognition involves a "key", which is a ligand such as a drug, and a "lock", which is a receptor.

The discovery of penicillin was a serendipitous (i.e. chance) discovery. Another, more advanced approach to drug discovery is rational drug design. The method is underpinned by an understanding of the biological targets of the drugs, including enzymes, receptors, and other proteins. In the late 19th century, Paul Ehrlich observed the selective affinity of dyes for different tissues and proposed the existence of chemoreceptors in our bodies. [8] [9] Receptors were believed to be the specific binding sites for drugs. [8] The drug-receptor recognition was described as a key-and-lock interplay by Emil Fischer in the early 1890s. [10] It was later found that the receptors can either be stimulated or inhibited by chemotherapeutic agents to attain the desired physiological response. [8] Once the ligand interacting with the target macromolecule is identified, drug candidates can be designed and optimized based on the structure-activity relationship. [10] Nowadays, artificial intelligence is employed in drug design to predict drug-protein interactions, drug activity, the 3D configuration of proteins, etc. [10]

Evidence-based medicine

Evidence-based medicine is defined as deploying the best current scientific evidence that is available to give the best treatment and make the best decision effectively and efficiently. [11] Clinical guidelines are developed based on scientific evidence; for example, the ACC/AHA guidelines (for cardiovascular diseases), the GOLD guidelines (for chronic obstructive pulmonary disease), the GINA guidelines (for asthma), etc. They convert and classify the evidence using a systematic method, aiming to provide care with quality. [12] The guidelines cannot substitute clinical judgment, as they cannot meet all the circumstances. [12] Healthcare professionals can use the clinical guidelines as references or evidence to support their clinical judgement when prescribing therapy to patients.

Example: Clinical Guideline for controlling blood pressure (hypertension)

If there is an Asian male patient who is 40 years old and has recently been diagnosed with high blood pressure (with a blood pressure of 140/90) and without any other chronic diseases (comorbidities), such as type-2 diabetes, gout, benign prostatic hyperplasia, etc. His estimated 10-year risk of cardiovascular disease is 15%.

According to the NICE 2019 Hypertension guideline, the healthcare professional can consider starting anti-hypertensive therapy after a discussion with the patient. [13] The first-line therapy will be either an Angiotensin Converting Enzyme Inhibitor (ACEi) or an Angiotensin receptor blocker (ARB) (if the patient cannot tolerate ACEi). [13] If the blood pressure of the patient is not well controlled, the healthcare professionals can consider adding a calcium channel blocker (CCB) [14] or a Thiazide-like diuretic to the previous therapy, i,e, ACEi or ARBs with a CCB or a thiazide-like diuretic. [13]

Personalized medicine

Summary of pharmacokinetics and pharmacodynamics. Pharmacokinetics and Pharmacodynamics.svg
Summary of pharmacokinetics and pharmacodynamics.

Every patient has their own body condition, for example, kidney function, liver function, genetic variations, medical history, etc. These are all the factors that should be considered by healthcare professionals before giving any pharmacological therapy. Most importantly, the advancing technology in genetics guides us to have more insight into the linkage between health and genes. [15] In pharmacological therapy, two areas of study are evolving: pharmacogenetics and pharmacogenomics. Age will affect the pharmacokinetics and pharmacodynamics of drugs, and hence the efficacy of the therapy. The effect of age causes deterioration of organ function, [16] like liver function and kidney function. Pharmacokinetics is the study of drugs' effects on absorption, distribution, metabolism, and elimination. Pharmacodynamics is the study of drugs' effects on our body and their mechanisms.

Pharmacogenetics and pharmacogenomics

Pharmacogenetics is defined as the study of inherited genes causing different drug metabolisms that vary from each other, such as the rate of metabolism and metabolites. [17] Pharmacogenomics is defined as the study of associating the drug response with one's gene. [18] Both terms are similar in nature, so they are used interchangeably.

Multiple alleles can contribute together to a change in response to a drug by expressing a different form of an enzyme that responds differently than the normal ones. [17] The different forms of enzymes (phenotypes) include ultra-rapid metabolizers, moderate metabolizers, no-enzyme activity, etc. The genetic variations can also be used to match the particular adverse drug reaction in order to prevent the patient from suffering the unfavorable outcomes. [19] The genetic make-up can affect the pharmacokinetics .

Example: Azathioprine Therapy

Azathioprine is an immunomodulator for inflammatory bowel disease, for instance. Its metabolite relies on two different enzymes (TPMT and NUDT15) to eliminate its effect on our body during its metabolism. If the patient has the phenotype of the enzymes that metabolize it poorly, i.e., the poor metabolizer, more toxic metabolites are accumulated in the body. Thus, the patient has a greater risk of the related side-effect. [20] The side effect causes the adjustment of dosage [20] or switching to another drug.

Example: Omalizumab Therapy

Omalizumab is a humanized monoclonal antibody for the treatment of various allergic diseases, including asthma, urticaria, and allergic rhinitis. [21] It targets the immunoglobulin E (IgE) in human body, which plays an important role in allergic reactions. [22] The efficacy of omalizumab may vary among patients. To identify responders to omalizumab, the level of several biomarkers can be measured, including serum eosinophils, fractional exhaled nitric oxide, and serum IgE. [22] [23] For instance, patients with higher baseline eosinophil counts are likely to respond better to omalizumab therapy. [23]

Medication compliance

Medication compliance is defined as the degree to which the patient follows the therapy that is recommended by healthcare professionals. [1] There are direct and indirect methods to evaluate compliance. Direct method refers to the measurement that the healthcare professionals observed or measure the patient's drug-taking behavior. Indirect method refers to the healthcare professionals do not observe or measure the drug-taking behavior of the patient but use the other source of information to evaluate the compliance.

The direct method includes measurement of drug (or the corresponding metabolite) concentration, [1] [24] while the indirect method includes pill counting [1] [24] and the self-report from the patient. [1] [24] The direct method is more time-consuming, more expensive, more invasive, but it is more accurate. [1] The indirect method has a lower accuracy but is easier to administer to the patient. [1] If the patient fails to comply with treatment, for example, by not taking the medication according to the instructions, it leads to risk and a poor treatment outcome.

Example: Tuberculosis treatment

For tuberculosis patients, directly observed therapy is still part of the treatment. [25] This is to increase medication compliance. [26] This is to prevent treatment failure, relapse, and transmission in the community. [27] Apart from the traditional direct observed therapy (DOT), there is another method proposed to try increasing medication compliance. Video-observed therapy (VOT) is one of the methods. It has some advantages and disadvantages. It reduces the cost of healthcare and the travel costs for the patient. [26] The downside of the intervention is the need for quality control training as it would be hard to confirm the patient's adherence. [26]

Related Research Articles

<span class="mw-page-title-main">Antacid</span> Substance that relieves stomach problems

An antacid is a substance which neutralizes stomach acidity and is used to relieve heartburn, indigestion or an upset stomach. Some antacids have been used in the treatment of constipation and diarrhea. Marketed antacids contain salts of aluminium, calcium, magnesium, or sodium. Some preparations contain a combination of two salts, such as magnesium carbonate and aluminium hydroxide.

<span class="mw-page-title-main">ACE inhibitor</span> Class of medications used primarily to treat high blood pressure

Angiotensin-converting-enzyme inhibitors are a class of medication used primarily for the treatment of high blood pressure and heart failure. This class of medicine works by causing relaxation of blood vessels as well as a decrease in blood volume, which leads to lower blood pressure and decreased oxygen demand from the heart.

<span class="mw-page-title-main">Allopurinol</span> Medication

Allopurinol is a medication used to decrease high blood uric acid levels. It is specifically used to prevent gout, prevent specific types of kidney stones and for the high uric acid levels that can occur with chemotherapy. It is taken by mouth or injected into a vein.

<span class="mw-page-title-main">Amitriptyline</span> Tricyclic antidepressant

Amitriptyline, sold under the brand name Elavil among others, is a tricyclic antidepressant primarily used to treat major depressive disorder, a variety of pain syndromes such as neuropathic pain, fibromyalgia, migraine and tension headaches. Due to the frequency and prominence of side effects, amitriptyline is generally considered a second-line therapy for these indications.

<span class="mw-page-title-main">Clopidogrel</span> Antiplatelet medication

Clopidogrel — sold under the brand name Plavix, among others — is an antiplatelet medication used to reduce the risk of heart disease and stroke in those at high risk. It is also used together with aspirin in heart attacks and following the placement of a coronary artery stent. It is taken by mouth. Its effect starts about two hours after intake and lasts for five days.

<span class="mw-page-title-main">Isoniazid</span> Antibiotic for treatment of tuberculosis

Isoniazid, also known as isonicotinic acid hydrazide (INH), is an antibiotic used for the treatment of tuberculosis. For active tuberculosis, it is often used together with rifampicin, pyrazinamide, and either streptomycin or ethambutol. For latent tuberculosis, it is often used alone. It may also be used for atypical types of mycobacteria, such as M. avium, M. kansasii, and M. xenopi. It is usually taken by mouth, but may be used by injection into muscle.

Antihypertensives are a class of drugs that are used to treat hypertension. Antihypertensive therapy seeks to prevent the complications of high blood pressure, such as stroke, heart failure, kidney failure and myocardial infarction. Evidence suggests that reduction of the blood pressure by 5 mmHg can decrease the risk of stroke by 34% and of ischaemic heart disease by 21%, and can reduce the likelihood of dementia, heart failure, and mortality from cardiovascular disease. There are many classes of antihypertensives, which lower blood pressure by different means. Among the most important and most widely used medications are thiazide diuretics, calcium channel blockers, ACE inhibitors, angiotensin II receptor antagonists (ARBs), and beta blockers.

Atenolol is a beta blocker medication primarily used to treat high blood pressure and heart-associated chest pain. Atenolol, however, does not seem to improve mortality in those with high blood pressure. Other uses include the prevention of migraines and treatment of certain irregular heart beats. It is taken by mouth or by injection into a vein. It can also be used with other blood pressure medications.

<span class="mw-page-title-main">Abacavir</span> Chemical compound

Abacavir, sold under the brand name Ziagen among others, is a medication used to treat HIV/AIDS. Similar to other nucleoside analog reverse-transcriptase inhibitors (NRTIs), abacavir is used together with other HIV medications, and is not recommended by itself. It is taken by mouth as a tablet or solution and may be used in children over the age of three months.

<span class="mw-page-title-main">Pharmacogenomics</span> Study of the role of the genome in drug response

Pharmacogenomics is the study of the role of the genome in drug response. Its name reflects its combining of pharmacology and genomics. Pharmacogenomics analyzes how the genetic makeup of a patient affects their response to drugs. It deals with the influence of acquired and inherited genetic variation on drug response, by correlating DNA mutations with pharmacokinetic, pharmacodynamic, and/or immunogenic endpoints.

<span class="mw-page-title-main">Polypharmacy</span> Use of five or more medications daily

Polypharmacy (polypragmasia) is an umbrella term to describe the simultaneous use of multiple medicines by a patient for their conditions. Most commonly it is defined as regularly taking five or more medicines but definitions vary in where they draw the line for the minimum number of drugs. Polypharmacy is often the consequence of having multiple long-term conditions, also known as multimorbidity. An excessive number of medications is worrisome, especially for older patients with many chronic health conditions, because this increases the risk of an adverse event in those patients.

Omalizumab, sold under the brand name Xolair, is a medication used to treat asthma, nasal polyps, and urticaria (hives).

<span class="mw-page-title-main">Tuberculosis management</span>

Tuberculosis management describes the techniques and procedures utilized for treating tuberculosis (TB).

An adverse effect is an undesired harmful effect resulting from a medication or other intervention, such as surgery. An adverse effect may be termed a "side effect", when judged to be secondary to a main or therapeutic effect. The term complication is similar to adverse effect, but the latter is typically used in pharmacological contexts, or when the negative effect is expected or common. If the negative effect results from an unsuitable or incorrect dosage or procedure, this is called a medical error and not an adverse effect. Adverse effects are sometimes referred to as "iatrogenic" because they are generated by a physician/treatment. Some adverse effects occur only when starting, increasing or discontinuing a treatment. Adverse effects can also be caused by placebo treatments . Using a drug or other medical intervention which is contraindicated may increase the risk of adverse effects. Adverse effects may cause complications of a disease or procedure and negatively affect its prognosis. They may also lead to non-compliance with a treatment regimen. Adverse effects of medical treatment resulted in 142,000 deaths in 2013 up from 94,000 deaths in 1990 globally.

Combination therapy or polytherapy is therapy that uses more than one medication or modality. Typically, the term refers to using multiple therapies to treat a single disease, and often all the therapies are pharmaceutical. 'Pharmaceutical' combination therapy may be achieved by prescribing/administering separate drugs, or, where available, dosage forms that contain more than one active ingredient.

In medicine, patient compliance describes the degree to which a patient correctly follows medical advice. Most commonly, it refers to medication or drug compliance, but it can also apply to other situations such as medical device use, self care, self-directed exercises, or therapy sessions. Both patient and health-care provider affect compliance, and a positive physician-patient relationship is the most important factor in improving compliance. Access to care plays a role in patient adherence, whereby greater wait times to access care contributing to greater absenteeism. The cost of prescription medication also plays a major role.

<span class="mw-page-title-main">Multidrug-resistant tuberculosis</span> Medical condition

Multidrug-resistant tuberculosis (MDR-TB) is a form of tuberculosis (TB) infection caused by bacteria that are resistant to treatment with at least two of the most powerful first-line anti-TB medications (drugs): isoniazid and rifampin. Some forms of TB are also resistant to second-line medications, and are called extensively drug-resistant TB (XDR-TB).

<span class="mw-page-title-main">Brivaracetam</span> Medication used to treat seizures

Brivaracetam, sold under the brand name Briviact among others, is a chemical analog of levetiracetam, is a racetam derivative with anticonvulsant (antiepileptic) properties. It is marketed by the pharmaceutical company UCB.

Treatment as prevention (TasP) is a concept in public health that promotes treatment as a way to prevent and reduce the likelihood of HIV illness, death and transmission from an infected individual to others. Expanding access to earlier HIV diagnosis and treatment as a means to address the global epidemic by preventing illness, death and transmission was first proposed in 2000 by Garnett et al. The term is often used to talk about treating people that are currently living with human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) to prevent illness, death and transmission. Although some experts narrow this to only include preventing infections, treatment prevents illnesses such as tuberculosis and has been shown to prevent death. The dual impact on well-being and its 100% effectiveness in reducing transmission makes TasP the most important element in the HIV prevention toolkit. In relation to HIV, antiretroviral therapy (ART) is a three or more drug combination therapy that is used to decrease the viral load, or the measured amount of virus, in an infected individual. Such medications are used as a preventative for infected individuals to not only spread the HIV virus to their negative partners but also improve their current health to increase their lifespans. Other names for ART include highly active antiretroviral therapy (HAART), combination antiretroviral therapy (cART), triple therapy and triple drug cocktail. When taken correctly, ART is able to diminish the presence of the HIV virus in the bodily fluids of an infected person to a level of undetectability. Undetectability ensures that infection does not necessarily have an effect on a person's general health, and that there is no longer a risk of passing along HIV to others. Consistent adherence to an ARV regimen, monitoring, and testing are essential for continued confirmed viral suppression. Treatment as prevention rose to great prominence in 2011, as part of the HPTN 052 study, which shed light on the benefits of early treatment for HIV positive individuals.

Additive effect in pharmacology describes the situation when the combining effects of two drugs equal the sum of the effects of the two drugs acting independently. The concept of additive effect is derived from the concept of synergy. It was introduced by the scientists in pharmacology and biochemistry fields in the process of understanding the synergistic interaction between drugs and chemicals over the century.

References

  1. 1 2 3 4 5 6 7 Simon, Steven T.; Kini, Vinay; Levy, Andrew E.; Ho, P. Michael (2021-08-11). "Medication adherence in cardiovascular medicine". BMJ (Clinical Research Ed.). 374: n1493. doi:10.1136/bmj.n1493. ISSN   1756-1833. PMID   34380627. S2CID   236970676.
  2. 1 2 3 "Historical Evolution of Pharmacy Practice". Encyclopedia of pharmacy practice and clinical pharmacy. Vol. 1. Zaheer-ud-din Babar. Amsterdam, Netherlands. 2019. pp. 191–202. ISBN   978-0-12-812736-0. OCLC   1110705461.{{cite book}}: CS1 maint: others (link)
  3. ↑ Thum Bonanno, Sarah; Gill, Jennifer; Davies, James; Wlodarski, Michal; Taylor, David (2012). From making medicines to optimising outcomes : the evolution of a profession 1912-2012. Federation Internationale Pharmaceutique. OCLC   926313996.
  4. 1 2 3 4 Barrett, Jeffrey S. (2022). Fundamentals of drug development. Hoboken, NJ. ISBN   978-1-119-91327-6. OCLC   1333930216.
  5. 1 2 3 4 Duffin, Jacalyn (1999). "Five: History of Pharmacology". History of medicine : a scandalously short introduction. Toronto: University of Toronto Press. pp. 90–114. ISBN   0-8020-0949-2. OCLC   40982537.
  6. 1 2 Hagan, Paul (2009). "Schistosomiasis – a rich vein of research". Parasitology. 136 (12): 1611–1619. doi:10.1017/S003118200999093X. ISSN   0031-1820. PMID   19691867. S2CID   44279233.
  7. 1 2 Sneader, Walter (2005). "Antibiotics". Drug discovery : a history. Chichester, England: Wiley. pp. 287–318. ISBN   978-0-470-01553-7. OCLC   154714913.
  8. 1 2 3 4 5 Drews, Jürgen (2000-03-17). "Drug Discovery: A Historical Perspective". Science. 287 (5460): 1960–1964. doi:10.1126/science.287.5460.1960. ISSN   0036-8075. PMID   10720314.
  9. ↑ "Drugs Originating from the Screening of Dyes", Drug Discovery, Chichester, UK: John Wiley & Sons, Ltd, pp. 375–402, 2006-01-27, doi:10.1002/0470015535.ch27, ISBN   978-0-470-01553-7 , retrieved 2023-04-03
  10. 1 2 3 Doytchinova, Irini (2022-02-23). "Drug Design—Past, Present, Future". Molecules. 27 (5): 1496. doi: 10.3390/molecules27051496 . ISSN   1420-3049. PMC   8911833 . PMID   35268598.
  11. ↑ Li, Shu; Cao, Meijuan; Zhu, Xuejiao (September 2019). "Evidence-based practice: Knowledge, attitudes, implementation, facilitators, and barriers among community nurses—systematic review". Medicine. 98 (39): e17209. doi:10.1097/MD.0000000000017209. ISSN   0025-7974. PMC   6775415 . PMID   31574830.
  12. 1 2 Grundy, Scott M.; Stone, Neil J.; Bailey, Alison L.; Beam, Craig; Birtcher, Kim K.; Blumenthal, Roger S.; Braun, Lynne T.; de Ferranti, Sarah; Faiella-Tommasino, Joseph; Forman, Daniel E.; Goldberg, Ronald; Heidenreich, Paul A.; Hlatky, Mark A.; Jones, Daniel W.; Lloyd-Jones, Donald (2019-06-18). "2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines". Circulation. 139 (25): e1082–e1143. doi:10.1161/CIR.0000000000000625. ISSN   0009-7322. PMC   7403606 . PMID   30586774.
  13. 1 2 3 "Recommendations | Hypertension in adults: diagnosis and management | Guidance | NICE". www.nice.org.uk. 28 August 2019. Retrieved 2023-04-08.
  14. ↑ Whelton, Paul K.; Carey, Robert M.; Aronow, Wilbert S.; Casey, Donald E.; Collins, Karen J.; Dennison Himmelfarb, Cheryl; DePalma, Sondra M.; Gidding, Samuel; Jamerson, Kenneth A.; Jones, Daniel W.; MacLaughlin, Eric J.; Muntner, Paul; Ovbiagele, Bruce; Smith, Sidney C.; Spencer, Crystal C. (2018). "2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines". Hypertension. 71 (6): e13–e115. doi:10.1161/HYP.0000000000000065. ISSN   0194-911X. PMID   29133356. S2CID   34986818.
  15. ↑ Goetz, Laura H.; Schork, Nicholas J. (2018). "Personalized medicine: motivation, challenges, and progress". Fertility and Sterility. 109 (6): 952–963. doi:10.1016/j.fertnstert.2018.05.006. ISSN   1556-5653. PMC   6366451 . PMID   29935653.
  16. ↑ Andres, Tate M.; McGrane, Tracy; McEvoy, Matthew D.; Allen, Brian F. S. (2019). "Geriatric Pharmacology: An Update". Anesthesiology Clinics. 37 (3): 475–492. doi:10.1016/j.anclin.2019.04.007. ISSN   1932-2275. PMID   31337479. S2CID   196519969.
  17. 1 2 Khalil, Islam A. (2021-11-24). Introductory Chapter. IntechOpen. ISBN   978-1-83969-218-5.
  18. ↑ Pharmacogenomics : a primer for clinicians. Jerika T. Lam, Mary A. Gutierrez, Samit Shah. [New York]. 2021. ISBN   978-1-260-45710-0. OCLC   1242235520.{{cite book}}: CS1 maint: others (link)
  19. ↑ López-Fernández, Luis A. (2022-02-22). Pharmacogenetics to Avoid Adverse Drug Reactions. MDPI, Basel. ISBN   978-3-0365-3344-5.
  20. 1 2 Dean, Laura (2012), Pratt, Victoria M.; Scott, Stuart A.; Pirmohamed, Munir; Esquivel, Bernard (eds.), "Azathioprine Therapy and TPMT and NUDT15 Genotype", Medical Genetics Summaries, Bethesda (MD): National Center for Biotechnology Information (US), PMID   28520349 , retrieved 2023-03-12
  21. ↑ Okayama, Yoshimichi; Matsumoto, Hisako; Odajima, Hiroshi; Takahagi, Shunsuke; Hide, Michihiro; Okubo, Kimihiro (2020-04-01). "Roles of omalizumab in various allergic diseases". Allergology International. 69 (2): 167–177. doi:10.1016/j.alit.2020.01.004. ISSN   1323-8930. PMID   32067933. S2CID   211160441.
  22. 1 2 Kawakami, Toshiaki; Blank, Ulrich (2016-12-01). "From IgE to Omalizumab". The Journal of Immunology. 197 (11): 4187–4192. doi:10.4049/jimmunol.1601476. ISSN   0022-1767. PMC   5123831 . PMID   27864548.
  23. 1 2 Tabatabaian, Farnaz; Ledford, Dennis K. (2018-04-03). "Omalizumab for severe asthma: toward personalized treatment based on biomarker profile and clinical history". Journal of Asthma and Allergy. 11: 53–61. doi:10.2147/JAA.S107982. PMC   5892947 . PMID   29662320.
  24. 1 2 3 Farmer, Kevin C. (1999-06-01). "Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice". Clinical Therapeutics. 21 (6): 1074–1090. doi:10.1016/S0149-2918(99)80026-5. ISSN   0149-2918. PMID   10440628.
  25. ↑ Haas, Michelle K.; Belknap, Robert W. (2018). "Updates in the Treatment of Active and Latent Tuberculosis". Seminars in Respiratory and Critical Care Medicine. 39 (3): 297–309. doi:10.1055/s-0038-1660863. ISSN   1098-9048. PMID   30071545. S2CID   51907855.
  26. 1 2 3 Garfein, Richard S.; Doshi, Riddhi P. (2019). "Synchronous and asynchronous video observed therapy (VOT) for tuberculosis treatment adherence monitoring and support". Journal of Clinical Tuberculosis and Other Mycobacterial Diseases. 17: 100098. doi:10.1016/j.jctube.2019.100098. ISSN   2405-5794. PMC   6904830 . PMID   31867442.
  27. ↑ Alipanah, Narges; Jarlsberg, Leah; Miller, Cecily; Linh, Nguyen Nhat; Falzon, Dennis; Jaramillo, Ernesto; Nahid, Payam (2018). "Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies". PLOS Medicine. 15 (7): e1002595. doi:10.1371/journal.pmed.1002595. ISSN   1549-1676. PMC   6029765 . PMID   29969463.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.